Journey Medical (DERM) Fundamental Analysis: Revenue, Earnings & Valuation

7.99 / 10

Outperform

Fundamental rating is Outperform with an 8.0/10 score. Strengths: inventory turnover, interest coverage, asset‑MV, revenue‑MV, PB‑ROE. Weak spots: fixed‑asset turnover and income‑tax ratio. Overall fund score 7.99, driven by strong asset‑MV and revenue‑MV contributions.

Analysis Checks(6/10)

Revenue-MV

Value-0.56

Score3/3

Weight33.33%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value7.68

Score1/3

Weight-4.06%

1M Return-1.40%

Inventory turnover ratio

Value1.18

Score2/3

Weight-2.10%

1M Return-0.66%

Accounts receivable turnover ratio

Value3.25

Score1/3

Weight-4.71%

1M Return-1.57%

PB-ROE

Value0.87

Score2/3

Weight37.37%

1M Return8.98%

Income tax / Total profit (%)

Value-0.59

Score0/3

Weight-4.26%

1M Return-1.54%

Fixed assets turnover ratio

Value274.95

Score1/3

Weight-3.51%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.11%

1M Return-0.73%

Cost of sales ratio (%)

Value33.82

Score2/3

Weight-2.08%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight52.14%

1M Return13.09%

Is DERM fundamentally strong?

DERM scores 7.99/10 on fundamentals and holds a Discounted valuation at present. Backed by its -44.31% ROE, -14.58% net margin, -18.19 P/E ratio, 6.14 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.